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Abstract 
Background: The effectiveness of long-lasting insecticidal nets (LLIN), the primary method for preventing malaria 
in Africa, is compromised by evolution and spread of pyrethroid resistance. Further gains require new insecticides 
with novel modes of action. Chlorfenapyr is a pyrrole insecticide that disrupts mitochrondrial function and confers no 
cross-resistance to neurotoxic insecticides. Interceptor® G2 LN (IG2) is an insecticide-mixture LLIN, which combines 
wash-resistant formulations of chlorfenapyr and the pyrethroid alpha-cypermethrin. The objective was to determine 
IG2 efficacy under controlled household-like conditions for personal protection and control of wild, pyrethroid-resist-
ant Anopheles funestus mosquitoes.
Methods: Experimental hut trials tested IG2 efficacy against two positive controls—a chlorfenapyr-treated net and a 
standard alpha-cypermethrin LLIN, Interceptor LN (IG1)—consistent with World Health Organization (WHO) evalua-
tion guidelines. Mosquito mortality, blood-feeding inhibition, personal protection, repellency and insecticide-induced 
exiting were recorded after zero and 20 washing cycles. The trial was repeated and analysed using multivariate and 
meta-analysis.
Results: In the two trials held in NE Tanzania, An. funestus mortality was 2.27 (risk ratio 95% CI 1.13–4.56) times greater 
with unwashed Interceptor G2 than with unwashed Interceptor LN (p = 0.012). There was no significant loss in mortal-
ity with IG2 between 0 and 20 washes (1.04, 95% CI 0.83–1.30, p = 0.73). Comparison with chlorfenapyr treated net 
indicated that most mortality was induced by the chlorfenapyr component of IG2 (0.96, CI 0.74–1.23), while com-
parison with Interceptor LN indicated blood-feeding was inhibited by the pyrethroid component of IG2 (IG2: 0.70, CI 
0.44–1.11 vs IG1: 0.61, CI 0.39–0.97). Both insecticide components contributed to exiting from the huts but the contri-
butions were heterogeneous between trials (heterogeneity Q = 36, P = 0.02). WHO susceptibility tests with pyrethroid 
papers recorded 44% survival in An. funestus.
Conclusions: The high mortality recorded by IG2 against pyrethroid-resistant An. funestus provides first field evi-
dence of high efficacy against this primary, anthropophilic, malaria vector.
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Background
Long-lasting insecticidal nets (LLINs) are essential for 
malaria transmission control in sub-Saharan Africa [1]. 
The halving of the malaria burden over the last 15 years 
is largely attributed to increasing coverage of pyrethroid 
LLIN, which culminated in universal free distribution 
across all age groups in Africa [2]. Concurrent with this 
public health achievement and cultural shift in sleeping 
behaviour has been the evolution and spread of pyre-
throid resistance across Africa in the two primary vector 
mosquito species complexes.
Pyrethroids, owing to their efficacy, safety and low-
cost were once the only insecticides approved for use on 
LLINs [3]. Since 2015, further reduction in the annual 
malaria burden has stalled, and pyrethroids are no 
longer deemed sufficient on their own [1]. The evolu-
tion of severe resistance was anticipated, and when the 
first signs of field failure were reported in 2007 [4], steps 
had already been taken to identify alternatives [5, 6]. 
The first active ingredient (AI) to be developed by pesti-
cide industry to enhance pyrethroid efficacy on nets was 
the synergist PBO [7, 8]. This supplemental compound, 
long used in domestic fly sprays to enhance pyrethroid 
toxicity, can neutralize metabolic mechanisms respon-
sible for resistance to pyrethroids. Several brands of 
pyrethroid-PBO LLIN are currently being scaled up in 
countries where monooxygenase resistance mechanisms 
are contributing to impairment or loss of malaria con-
trol [9–11]. Pyrethroid-PBO LLIN is no panacea; it can-
not neutralize all pyrethroid resistance mechanisms that 
have evolved, and this is no time for complacency. What 
is needed is an array of alternative insecticides that can 
complement the pyrethroids on Dual-AI LLIN. This is no 
trivial task as alternative insecticides for nets need to be 
safe to humans, toxic to mosquitoes, wash-tolerant on 
nets and exhibit no cross resistance to pyrethroids. One 
such insecticide, which is showing promise, is the pyr-
role chlorfenapyr [12]. After 15  years of development 
and evaluation in laboratory and small-scale experimen-
tal hut trials against anopheline mosquitoes [13–18], the 
first cluster randomized trials (CRT) of a LLIN that com-
bines chlorfenapyr with pyrethroid in a wash-tolerant 
formulation are currently underway and are due to report 
in 2021 in Tanzania, East Africa and in 2022 in Benin, 
West Africa. Epidemiological evidence of effectiveness 
against malaria in CRT is a prerequisite before the World 
Health Organization (WHO) will grant recommenda-
tion of any new class of LLIN for malaria control. Both 
CRTs are targeting the Anopheles gambiae complex: An. 
gambiae sensu stricto (s.s.) in NW Tanzania and Anoph-
eles coluzzii in Benin. However, a third primary vector 
has re-emerged, Anopheles funestus [19], and this spe-
cies is becoming the predominant vector along the east-
ern seaboard of Tanzania after a hiatus of several years 
when LLIN were first taken to scale in mass distribution 
campaigns and control of the then pyrethroid-suscepti-
ble An. funestus and An. gambiae was achieved [20, 21]. 
The return of both An. funestus and An. gambiae s.s. is in 
pyrethroid-resistant form.
The sibling species, vector competence and insecticide 
resistance status of the An. funestus complex has only 
recently been characterized in Tanzania [22]. Molecular 
identification of collections from 2005–2014 in NE Tan-
zania revealed An. funestus s.s. (97%) as the predominant 
species and Anophelesrivulorum (2%) and Anopheles 
leesoni (1%) as minor sibling species. Plasmodium fal-
ciparum CSP positivity was 8.3% for recently collected 
An. funestus s.s. [22]. Wucheria bancrofti infection rates 
decreased from 14.8% in the 2005–2007 archived speci-
mens to only 0.5% in newly collected specimens, with 
93% of filarial infections confined to An. funestus s.s. The 
high P. falciparum and decreasing W. bancrofti infections 
in An. funestus s.s. most likely reflects infection levels of 
these parasites in the human population and confirms its 
vectorial importance [22]. Vector surveys further south 
in coastal Bagamoyo and Kilombero valley produced 
similar trends and species ratios as NE Tanzania. In Bag-
amoyo, there was 84% An. funestus s.s., 13.6% An. leesoni, 
1.5% An. rivulorum, and 0.6% Anopheles parensis [23]. In 
Kilombero valley, 97% were An. funestus s.s., 2% An. riv-
orulum and 1% An. leesoni [24].
Anopheles funestus s.s. and An. gambiae s.s. in addi-
tion to being pyrethroid resistant are naturally highly 
anthropophagic and endophilic. These are the primary 
vector species to target with the new generation insec-
ticides like chlorfenapyr. Unlike pyrethroids and other 
conventional public health insecticides which are neuro-
toxic, chlorfenapyr disrupts the oxidative pathways that 
enable proton transfer, conversion of ADP to ATP and 
cellular respiration in mitochondria [15, 25]. With its 
non-neurological mode of action, chlorfenapyr shows no 
cross resistance to insecticide classes normally used for 
vector control and hence is a leading candidate for tar-
geting vector species resistant to standard neurotoxic 
insecticides [13, 17]. When evaluated on hand-treated 
mosquito nets against wild mosquitoes in experimental 
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huts, chlorfenapyr showed improved control of mosqui-
toes resistant to WHO-approved insecticides [14, 26].
Interceptor G2 LN (IG2) is a Dual-AI LLIN developed 
by the manufacturer BASF SE which is designed to pro-
vide protection against pyrethroid-resistant mosquitoes 
by means of a mixture of chlorfenapyr and alpha-cyper-
methrin in a long-lasting wash-resistant formulation. The 
first experimental hut trials of IG2, undertaken in Benin, 
Burkina Faso and Cote d’Ivoire in West Africa, targeted 
members of the An gambiae complex: An coluzzii, An 
gambiae s.s. and Anopheles arabiensis [15, 27, 28]. The 
present paper reports on sequential hut trials in NE Tan-
zania on the East African seaboard designed to assess the 
efficacy of Interceptor G2 LN against the primary East 
African vectors An. funestus s.s. and Anopheles gambiae 
s.s. IG2 was tested unwashed and after 20 standardized 
washes as proxy for an ageing net consistent with WHO 
guidelines for evaluating LLIN. Two other net types 
served as positive controls: the pyrethroid-only Intercep-
tor LN (IG1) and a net hand-treated with chlorfenapyr 
SC formulation. While it was anticipated that pyrethroid 
resistant An. funestus s.s. and An. gambiae s.s. would both 
be present, on these two occasions only An. funestus s.s. 
was present in significant densities.
Methods
Study site and experimental huts
Two experimental hut studies were conducted in Muheza 
district, Tanga region, at the field station in Zeneti (5°13′ 
S, 38°39′ E, 193 m altitude), where An. gambiae s.s. and 
An. funestus s.s. are the major malaria vectors [20, 22]. 
Polymerase chain reaction sibling species analysis of 500 
An. funestus collected from Zenet between 2016–2017 
results showed all were An. funestus s.s. In World Health 
Organization insecticide susceptibility tests using per-
methrin papers conducted on F1 adult mosquitoes from 
Zeneti in the year before the hut trials, mortality was 56% 
among An. gambiae s.s. and 62% among An. funestus. In 
intensity bottle bioassay An. gambiae s.s. showed 30-fold 
resistance to permethrin relative to susceptible Kisumu 
strain [30]. There was no resistance to carbamates or 
organophosphates.
The WHO Phase II evaluation of Interceptor G2 
was conducted in 6 experimental huts of the East Afri-
can design [31]. The operating principle of the huts is 
described in WHO LLIN evaluation guidelines [32]. 
The hut design allows host-seeking mosquitoes unfet-
tered access though two open eave gaps, 5 cm deep and 
3 m wide, between wall and roof on two sides of the hut, 
attracted by the human host sleeping inside, and captures 
surviving mosquitoes exiting into window traps fitted on 
two of the walls or into verandah traps accessed through 
eave gaps above the walls. Other features include a ceiling 
lined with hessian sackcloth similar to thatch, a corru-
gated iron roof, a concrete plinth and water-filled moat 
to deny entry to scavenging ants. The eaves of the two 
unscreened verandahs were baffled inwardly to funnel 
host-seeking mosquitoes into the hut and to deter exit-
ing through the same eave gaps. Two screened and closed 
veranda traps located on the other two sides of the hut, 
and two baffled window traps, capture any mosquito that 
exit the rooms via the two open eaves or windows. With 
this modification to the traditional verandah hut design 
there was no need to make any correction for escaping 
mosquitoes because all escapees are recorded [31].
Experimental hut trial design
Two experimental huts trials were undertaken. The first 
trial was conducted over 54 collection nights between 
November and December 2015, the second trial was con-
ducted for 36 nights between May and July 2016. The fol-
lowing six treatment arms were included:
(i) Untreated polyester net,
(ii) Interceptor LN, unwashed
(iii) Interceptor LN, washed 20 times
(iv) Interceptor G2 LN, unwashed
(v) Interceptor G2 LN, washed 20 times
Polyester net, conventionally treated with chlorfenapyr 
SC formulation (Phantom 21% SC, BASF) at 200 mg/m2.
Washing of LLINs was done according to WHO Phase 
II protocols [32]. The interval between washes was 1 day 
which is the established regeneration time for Intercep-
tor G2 and Interceptor LN [8]. Each net was cut with six 
holes of 4  cm diameter to simulate wear and tear. For 
the washed nets, washing was done in 10 L of soap solu-
tion (2 g/l of Savon de Marseille). Nets were agitated for 
3  min by stirring with a pole, then allowed to soak for 
four minutes, and then stirred again for 3 min. The nets 
were rinsed twice using the same procedure with clean 
tap water. All nets were 100-denier. Three nets were used 
per treatment arm.
Treatments were rotated between huts each week (3 
nets tested 3 times over 9 days or 2 times over a 6-days) 
with sleepers rotated between huts and treatments each 
night using a randomized latin square design to adjust 
for variation in personal attractiveness to mosquitoes 
or hut positional effect. Each morning mosquitoes were 
collected and held for 72  h in cups with sugar solution 
to record any delayed mortality. All dead and surviv-
ing mosquitoes were retained on silica gel for molecu-
lar identification [33] and for genotyping of L1014S or 
L1014F kdr alleles using Taqman PCR [34].
The outcomes of the hut trials were:
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 (i) Deterrence—the proportional reduction of mos-
quito entry into huts with insecticide treated nets 
relative to huts with untreated nets
 (ii) Mortality—the proportion of mosquitoes killed by 
a treatment relative to the total numbers entering 
huts with that treatment
 (iii) Overall killing effect—the number of mosquitoes 
killed by a treatment relative to the number dying 
in the untreated control, as derived from the for-
mula: killing effect (%) = 100 (Kt-Ku)/Tu, where 
i) Kt is the number killed in the huts with treated 
nets, ii) Ku is the number dying in the huts with 
untreated nets, iii) Tu is the total entering the huts 
with untreated nets
 (iv) Blood-feeding inhibition—the proportional reduc-
tion blood-feeding in huts with treated nets rela-
tive to the proportion blood-feeding in huts with 
untreated nets
 (v) Personal protection—the reduction in the numbers 
of mosquitoes blood-feeding in huts with treated 
nets relative to numbers blood-feeding through 
untreated nets, as derived from the formula: % 
Personal protection = 100 (Bu-Bt)/Bu, where (i) 
Bu is the total number of blood-fed mosquitoes 
in the huts with untreated nets, and (ii) Bt is the 
total number of blood-fed mosquitoes in huts with 
treated nets
 (vi) Insecticide induced exiting–the proportional 
increase in exiting from huts with insecticide 
treated nets relative to the proportion exiting from 
huts with untreated nets
Chemical analysis
Netting samples were cut from each net before and 
after washing and after completion of the trial for 
determination of insecticide content. Determination 
of alpha-cypermethrin and chlorfenapyr content was 
performed at BASF (1st trial) and Walloon Agricul-
tural Research Centre (CRA-W) (2nd trial) using a 
draft CIPAC method jointly developed by CRA-W and 
BASF based on CIPAC 454/LN/M/3.1. The method 
involves extraction of alpha-cypermethrin and chlo-
rfenapyr by ultrasonication at ambient temperature 
for 30 min in heptane in the presence of dicyclohexyl 
phthalate as internal standard, by adding citric acid, 
and determination by gas chromatography with flame 
ionization detection (GCFID). The insecticide concen-
tration of each sample (g/kg) was converted to mg/m2 
before presentation.
Supplementary bioassay tests on nets used in the trials
Mosquito strains
Anopheles gambiae s.s. Kisumu, a laboratory insecticide 
susceptible strain, originally from Kenya.
Anopheles gambiae s.s. Zeneti, a pyrethroid resistant 
strain of An. gambiae s.s. from Zeneti village containing 
the L1014S pyrethroid resistance knockdown allele (kdr 
east) [29] and showing 30-fold resistance to permethrin 
relative to susceptible An. gambiae Kisumu.
WHO cone bioassays
These were conducted on standardised washed and 
unwashed nets to estimate the wash fastness of each 
net formulation. Five pieces were cut from each net and 
two replicates of five susceptible or resistant An. gam-
biae mosquitoes were exposed for 3 min. Mortality was 
scored at 24 h, 48 h and 72 h post-exposure.
Tunnel tests
These were conducted on standardised washed and 
unwashed pieces of Interceptor G2 LN netting after 0 
and 20 washes. A total of 100 susceptible and resistant 
mosquitoes were tested in tunnel tests in replicates of 
50 mosquitoes per test in accordance with WHO guide-
lines [32]. The tunnels were divided into two sections by 
a netting frame punctured with 9 holes slotted across 
the tunnel. In one section an anaesthetized guinea pig 
was housed unconstrained in a cage to attract mosqui-
toes from the release section overnight. Test conditions 
were 25 ± 2 °C and 80 ± 10% RH. Mosquito mortality was 
recorded after 24 h and 72 h holding periods.
Statistical analysis
Data were entered into an Excel database and transferred 
to Stata 11 (Stata Corp LP, College Station, TX, USA) for 
processing and analysis. Cone bioassays and tunnel test 
data were analysed using logistic regression for grouped 
data adjusting for clustering within replicate tests.
Proportional outcomes in the experimental hut trial 
(mortality, blood-feeding, exiting) related to each treat-
ment were assessed using logistic regression for grouped 
data adjusting for daily collected mosquitoes. In addition 
to the fixed effect of each treatment, each model included 
random effects to account for variation between the hut 
position and sleeper attractiveness. Comparison between 
numeric outcomes of treatments (personal protection, 
killing effect, deterrence) was analysed using negative 
binomial regression with adjustment for variation in the 
same covariates described above.
Risk ratios of mortality, blood-feeding and exiting rates 
the two trials were pooled using meta-analysis using 
a random-effects model STATA® statistical analysis 
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software package version 16 (Stata corporation, Collage 
Station, Texas 77,845 USA, 2019). Overall heterogeneity 
across trials was calculated using Cochrane’s Q test with 
a P value of less than 0.05 to indicate statistical hetero-




WHO susceptibility tests using permethrin and alpha-
cypermethrin treated papers were conducted against 
F1 progeny of mosquitoes collected from huts contain-
ing untreated nets before and during the trial. Mortality 
recorded using 0.75% permethrin papers was 46.7% for 
An. gambiae and 56.7% for An. funestus in the first trial 
(2015) and 43% and 52.6%, respectively in the second 
(2016), indicating resistance to pyrethroids in both spe-
cies. Mortality using 0.05% alpha-cypermethrin papers 
was 52.7% for An. gambiae during the first trial. Alpha-
cypermethrin papers were not available during the  2nd 
trial, but other alpha-cyano pyrethroids such as 0.05% 
deltamethrin and 0.05% lambdacyhalothrin gave a simi-
lar 73.8% and 50.6% mortality respectively. Concurrent 
mortality using the same insecticide test papers against 
susceptible An. gambiae Kisumu was 100% in each case. 
Insecticide resistance intensity testing showed Zenet field 
An. gambiae to have over 30-fold resistance to pyrethroid 
(permethrin) compared to susceptible An. gambiae 
Kisumu.
Phase II—experimental hut trials
Mosquito entry into experimental huts
The average number of mosquitoes entering and exit-
ing the hut are shown in Table  1. The geometric mean 
number of An. funestus collected during the first trial 
ranged from 0.6 to 1.5 per hut per night. During the 
second trial the geometric mean number of An. funestus 
ranged from 1.3 to 1.8 per hut per night. In both trials 
significantly fewer An. funestus were collected from the 
huts with chlorfenapyr CTN compared to the huts with 
the untreated nets. No consistent deterrent effect was 
observed with IG1 (alpha-cypermethin alone) or IG2 
compared to untreated nets.
Mortality and overall killing effect
The overall percentage mortality by treatment arm is 
shown in Fig.  1. Because chlorfenapyr shows the prop-
erty of delayed mortality, which reaches a zenith 72  h 
after mosquitoes enter into the huts with chlorfenapyr 
treated nets, both 24 h and 72 h mortality are presented 
in Table 2. Percentage mortality corrected for untreated 
net control is also shown.
In the first trial, control-corrected mortality of An. 
funestus after 24  h was 5–6% in the huts with the 
unwashed IG1 and in the huts with the IG1 washed 20 
times (Table  2). Mortality in these treatment arms was 
significantly different from the mortality in the huts with 
the unwashed IG2 (42%), the IG2 washed 20 times (44%) 
and the chlorfenapyr CTN (37%). After 72 h, control cor-
rected mortality was significantly higher than after 24 h 
across most of these treatments (Table 2). Mortality was 
significantly higher in the huts with the IG2 unwashed 
and washed 20 times compared with the IG1 unwashed 
and washed 20 times treatments.
In the second trial, the trend was slightly different. 
Control corrected mortality significantly increased once 
again between 24 and 72 h with the unwashed IG2 (from 
22 to 46%), the IG2 washed 20 times (from 6 to 41%) and 
the chlorfenapyr CTN (from 18 to 36%) (Table  2). But 
unlike the first trial, control-corrected mortality showed 
no significant change between 24 and 72  h with the 
unwashed IG1 (1.9% to 3.8%) and with the IG1washed 
Table 1 Anopheles funestus mosquitoes collected and exiting into verandah and window traps during the two experimental hut trials
The numbers in the same row sharing the same letter superscript do not differ significantly (p > 0.05)
Trial Effect Untreated net Interceptor LN Interceptor LN Interceptor G2 Interceptor G2 Chlorfenapyr CTN
0 washes 0 washes 20 washes 0 washes 20 washes 0 washes
1 Total number caught (mean/night) 139 (2.6) 94 (1.7) 97 (1.8) 63 (1.2) 133 (2.5) 54 (1.0)
Geometric mean per night (CI) 1.4a (0.9–1.9) 1.1ab (0.7–1.5) 1.3a (0.9–1.7) 0.9ab (0.6–1.2) 1.5a (1.0–2.1) 0.6b (0.4–0.9)
% Deterrence 0 32.4 30.2 54.7 4.3 61.2
2 Total number caught (mean/night) 111 (3.1) 80 (2.2) 78 (2.2) 103 (2.9) 86 (2.4) 74 (2.1)
Geometric mean per night (CI) 1.8a (1.1–2.8) 1.5b (1.0–2.2) 1.8ab (1.2–2.4) 1.6ab (0.9–2.4) 1.3b (0.8–2.0) 1.3b (0.8–2.0)
% Deterrence 0 27.9 29.7 7.2 22.5 33.3
1 Total in verandah & window traps 59 74 83 51 107 32
% Exiting (95% C.I.) 42a (27–59) 79c (67–87) 86c (73–93) 81c (68–90) 80c (69–89) 59b (39–77)
2 Total in verandah & window traps 75 53 51 48 46 58
% Exiting (95% C.I.) 68ac (52–80) 66ac (51–79) 65c (54–75) 47b (31–63) 54bc (36–70) 78a (67–87)
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20 times (6.6% to 5.6%). Therefore, delayed mortality of 
An. funestus after 72 h was significantly pronounced only 
in the huts with the chlorfenapyr CTN, the unwashed 

























Fig. 1 Experimental hut trials of Interceptor G2 and Interceptor LN in NE Tanzania: mortality of free-flying Anopheles funestus after 72 h holding 
period
Table 2 Percentage mortality of Anopheles funestus corrected for control mortality 24 h and 72 h after exposure during the two 
experimental huts trials
The numbers in the same row sharing the same letter superscript do not differ significantly (p > 0.05)
Trial Effect Holding period Untreated net Interceptor LN Interceptor LN Interceptor G2 Interceptor G2 Chlorfenapyr CTN
Hours 0 washes 0 washes 20 washes 0 washes 20 washes 0 washes
1 Total number dead 24, 72 13, 29 14, 34 14, 33 30, 38 66, 92 23, 35
% Mortality, overall 24 9a1 (4–19) 15a1 (8–27) 14a1 (8–24) 48b1 (36–59) 50b1 (41–58) 43b1 (30–56)
% Mortality, control cor-
rected
24 - 6a1 (0–19) 6a1 (0–17) 42b1 (30–54) 44b1 (35–54) 37b1 (30–52)
% Mortality overall 72 21a2 (11–36) 37c2 (25–51) 34c2 (22–48) 60b1 (48–71) 70d2 (61–78) 65bd2 (48–78)
% Mortality, control cor-
rected
72 - 21a2 (5–33) 17a2 (2–34) 50b1 (34–62) 62c2 (51–72) 55bc2 (35–73)
2 Total number dead 24, 72 12, 14 10, 13 13, 14 31, 55 14, 42 20, 33
% Mortality, overall 24 11a1 (5–17) 13a1 (5–20) 17ac1 (8–25) 30b1 (21–39) 16ac1 (9–24) 27bc1 (17–37)
% Mortality, control cor-
rected
24 - 2a1 (0–10) 7a1 (0–16) 22b1 (12–32) 6a1 (1–15) 18b1 (7–30)
% Mortality overall 72 13a1 (7–19) 16a1 (8–24) 18a1 (9–27) 53b2 (44–63) 49b2 (38–59) 45b2 (33–55)
% Mortality, control cor-
rected
72 - 4a1 (0–13) 6a1 (0–16) 46b2 (35–58) 41b2 (29–53) 36b2 (23–48)
1 % Overall Killing Effect 24 - 5a 5ab 38b 41c 33ab
72 - 17b 13 b 30a 49a 44a
2 % Overall Killing Effect 24 - 0a 1a 17a 2a 7a
72 - 0a 0a 38b 26b 18b
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Natural mortality of An. funestus after 72 h in the huts 
with the untreated nets in the first trial was significantly 
lower (21%) than the overall mortality in huts with the 
IG1 unwashed (37%) or IG1 washed 20 times (34%). In 
the second trial, natural mortality after 72 h in huts with 
the untreated nets was lower (13%) than in the first trial 
(21%), but on this occasion the untreated nets showed no 
difference in mortality compared to IG1 unwashed (16%) 
or IG1 washed 20 times (18%) which also stayed low. 
A further difference between the two trials: in the first, 
both IG2 and IG1 showed significantly delayed mortality 
between 24 and 72 h, in the second trial only IG2 showed 
significantly delayed mortality between 24 and 72 h and 
not IG1.
Because the untreated net control showed 21% (trial 
1) and 13% (trial 2) mortality after the 72  h holding 
period, the observed mortality of IG2 presented in Fig. 1 
after 72  h observation was considerably higher (range: 
49–70%) than the control-corrected mortality (range: 
41–62%) presented in Table 2.
The ‘overall killing effect’ by the IG1 and IG2 interven-
tions were consistent with percentage mortality of the 
IG1 and IG2 treatments observed in the huts. In the first 
and second trials, IG1 killed up to 16% and 0% of An. 
funestus, respectively, and IG2 killed up to 49% and 38%, 
respectively.
Meta‑analysis of mortality
In the meta-analyses of mortality between the two 
trials, the comparison of relative risk between the 
unwashed IG2 and the untreated net was 3.36 (CI 2.3, 
4.9) (P = 0.001). The comparison of mortality relative risk 
between the chlorfenapyr CTN and untreated net, 3.24 
(CI 2.4, 4.2) (P = 0.001) was, therefore, quite similar to 
that of the unwashed IG2 and untreated net. The compar-
ison of relative risk between the unwashed IG1 and the 
untreated net was rather less (1.60, CI 1.1–2.3) (P = 0.01), 
indicating a smaller effect size of alpha-cypermethrin on 
mortality. The effect of the comparison between IG2 and 
IG1 was 2.27 (1.1, 4.6) (P = 0.012), confirming the greater 
contribution of chlorfenapyr than of alphacypermethrin 
to IG2 mortality. This was further confirmed by the com-
parison of chlorfenapyr CTN to IG2: the risk ratio was 
a non-significant 0.96 (0.7, 1.23) (P = 0.231) implying 
that chlorfenapyr was making most of the contribution 
to mortality in IG2 and not alpha-cypermethrin. The 
similarity of relative risk between unwashed IG2 and IG2 
after 20 washes (1.04, CI 0.8–1.3) (P = 0.73) indicated no 
loss of mortality effect in IG2 between 0 and 20 washes 
(Fig. 2a).
Blood feeding rates and personal protection
In the first trial, the percentage blood-feeding of An. 
funestus was significantly greater in the huts with the 
untreated net than in the huts with IG1 and IG2. There 
were no significant differences in blood-feeding rates 
between the huts with the IG1 or the IG2, with or with-
out washing (Table 3). Neither was there significant dif-
ference in percentage blood-feeding between untreated 
net and chlorfenapyr CTN nor evidence of blood-feed-
ing inhibition due to chlorfenapyr presence (percentage 
blood-feeding was greater in the huts with the chlor-
fenapyr CTN).
In the second trial, while the percentage blood-
feeding may have seemed greater in the huts with the 
untreated net than in the huts with the unwashed IG1 
or IG1 washed 20 times the differences were not signifi-
cant. Once again, no significant differences were evident 
between any of the IG1 and IG2 treatments. In the sec-
ond trial, the difference between the untreated net and 
the chlorfenapyr CTN was also non-significant. Seven of 
the eight treatments that did show some degree of blood-
feeding inhibition contained an alpha-cypermethrin 
component whether in IG1 or when twinned with chlo-
rfenapyr in IG2.
In the first trial, personal protection in huts with IG1 
and IG2 was significantly greater than in huts with the 
untreated nets. The chlorfenapyr net also showed signifi-
cantly greater personal protection compared to untreated 
nets. In the second trial, while the numbers of An. funes-
tus that were blood fed were also less in huts with the 
insecticide treated nets, neither the IG1, IG2 nor the 
chlorfenapyr treatments showed significant reduction in 
number blood-fed compared numbers blood-fed in huts 
with the untreated net. From these results it is not pos-
sible to conclude definitively that chlorfenapyr has no 
role in personal protection in huts with the chlorfenapyr 
treated net, but as regards personal protection in IG2, it 
would seem that that the alphacypermethrin component 
has the major role mediated through reduced blood-
feeding just as in IG1.
Meta‑analysis of percentage blood feeding
In the meta-analyses of blood-feeding between the 
two trials, the comparison of relative risk between the 
unwashed IG2 versus the untreated net was 0.70 (CI 
0.44, 1.11) (P = 0.133). The comparison of relative risk 
between the unwashed IG1 versus the untreated net was 
also quite similar (0.61, CI 0.39, 0.97) (P = 0.035) to that 
of IG2 above (Fig.  2b). The comparison of relative risk 
between the chlorfenapyr CTN versus the untreated 
net was 0.97 (CI 0.39–2.44) (P = 0.95). Considering 
these results in reverse order: chlorfenapyr treatment 
seems to have no effect on blood-feeding compared to 
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Fig. 2 a Interceptor G2  versus Interceptor LN: meta-analysis of the two hut trials: mortality. b Interceptor G2 vs Interceptor LN Metanalysis of the 
two trials: feeding. c Interceptor G2 vs Interceptor LN Metanalysis of the two trials: exophily
Table 3 Blood-feeding and blood-feeding inhibition of Anopheles funestus collected in the two experimental hut trials
The numbers in the same row sharing the same letter superscript do not differ significantly (p > 0.05)
Trial Effect Untreated net Interceptor LN Interceptor LN Interceptor G2 Interceptor G2 Chlorfenapyr CTN
0 washes 0 washes 20 washes 0 washes 20 washes 0 washes
1 Total number blood fed 36 14 16 11 23 20
% Blood fed (95% C.I.) 26ac (20–33) 15b (7–28) 17b (8–30) 18bc (10–29) 17b (10–29) 37a (22–55)
% Blood feeding inhibition 0 42 36 32 33 0
% Personal protection 0a 61bc 56bc 69b 36c 44bc
2 Total number blood fed 16 8 7 11 13 6
% Blood fed (95% C.I.) 14a (8–24) 10a (5–20) 9a (4–21) 11a (4–25) 15a (7–30) 8a (3–20)
% Blood feeding inhibition 0 31 38 26 0 44
% Personal protection 0a 50a 56a 31a 19a 63a
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no treatment. Alpha-cypermethrin was the sole AI con-
tributing to reduced blood-feeding in the comparison of 
IG1 to untreated net. The inference is, the contributing 
active ingredient to reduced blood-feeding in IG2 versus 
untreated net is the alpha-cypermethrin rather than the 
chlorfenapyr. Further, the meta-analysis of relative risk 
of the comparison of IG2 versus chlorfenapyr CTN was 
0.74 (0.3–2.0) (P = 0.67). This relative risk, being in the 
same direction as the relative risk between IG1 versus 
untreated net (0.61, 0.39–0.97) may support the interpre-
tation that the chlorfenapyr has little or no role in blood-
feeding in IG2 nor does it antagonize the positive effect 
alpha-cypermethrin has on reducing blood feeding in 
IG2 (Fig. 2b).
Exiting rates
In the first trial, mosquito exiting rates were signifi-
cantly higher in the huts with IG1, IG2 and chlorfenapyr 
CTN treatments compared to the huts with untreated 
nets (Table 1). In the second trial the exiting rates from 
huts with IG1, 1G2 and chlorfenapyr CTN were not sig-
nificantly different from exiting rates from huts with the 
untreated net nor from one another (Table 1).
Meta‑analysis of enhanced exiting
In the meta-analysis these differences between the first 
and second trials led to heterogeneity in several of the 
comparisons of relative risk for exiting rates between 
treatments. No comparison between IG2 and any other 
treatment (untreated net, alpha-cypermethrin net, 
chlorfenapyr net) was significantly different from unity 
(Fig. 2c).
Anopheles gambiae sensu lato
Abundance of An. gambiae was very low in trial 1 with 
only 42 mosquitoes collected from the six treatments 
over 54 nights. However, differences in mortality were 
observed at 72  h with significantly higher mortality 
observed in huts with unwashed IG2 and IG2 washed 20 
times (14/16) compared to IG1 (4/11) or untreated nets 
(1/10) (Supplementary file), which is consistent with the 
An. funestus dataset trends. Insufficient An. gambiae 
were collected during trial 2 for formal analysis.
Chemical analysis
The mean alpha-cypermethrin content in unwashed IG2 
for trial 2 (the WHO trial) was 2.81 g/kg (Table 4). The 
nets complied with the target dose of 2.4  g/kg ± 25% 
for 100 denier yarn. The mean chlorfenapyr content in 
unwashed IG2 for trial 2 was 5.22  g/kg. The nets com-
plied with the target dose of 4.8 g/kg ± 25%. The within-
net variation showed an acceptable homogeneity of 
active ingredient within the nets. After 20 washes the 
IG2 alpha-cypermethrin content for trial 2 was 1.65  g/
kg, corresponding to an overall alpha-cypermethrin 
retention of 59%. The chlorfenapyr content was 1.66 g/kg 
after 20 washes, corresponding to an overall chlorfenapyr 
retention of 32% for trial 2. Netting samples were not 
kept back pre-washing in trial 1 for chemical analysis and 
therefore retention of chlorfenapyr and alpha-cyperme-
thrin in IG2 after washing could not be accurately esti-
mated. However, chemical analyses were conducted after 
the nets had been washed and tested in the huts and data 
was consistent with trial 2 post-trial retention estimates 
(see Table  4). The mean alpha-cypermethrin content 
in unwashed IG1from trial 2 was 5.55  g/kg. The alpha-
cypermethrin content after twenty washes was 1.59 g/kg, 
corresponding to alpha-cypermethrin retention of 30% in 
IG1.
Supporting bioassay tests on Interceptor and Interceptor 
G2 nets used in the hut trials
The purpose of the supplementary bioassays was to sam-
ple netting from the IG2 and IG1 used in the experimen-
tal hut trials to 1) test bio-efficacy against pyrethroid 
resistant (Zenet) and susceptible (Kisumu) strains in 
mosquito bioassay, 2) confirm the bioefficacy of alpha-
cypermethrin and chlorfenapyr components after mul-
tiple washing, 3) examine the capacity of tunnel tests to 
predict the performance IG2 netting under simulated hut 
conditions to control An gambiae s.s.
Standard WHO Cone bioassay tests on nets with 
3 min exposure of the susceptible strain and a 72 h hold-
ing period, induced mortality of 96% and 100% on the 
unwashed IG1 and the IG1 washed 20 times. With the 
chlorfenapyr CTN, mortality was 90%, 95% and 100% 
after 24  h, 48  h and 72  h. For the unwashed IG2, mor-
tality was 100% after 24 h exposure. For IG2 washed 20 
times mortality was 62%, 72% and 86% after 24  h, 48  h 
and 72 h intervals (Fig. 3a).
(See figure on next page.)
Fig. 3 a Cone bioassay test on unwashed and 20 times washed Interceptor G2 and Interceptor LN nets using pyrethroid susceptible Anopheles 
gambiae Kisumu. b Cone bioassay test mortality on unwashed and 20 times washed Interceptor LN and Interceptor G2 nets using Anopheles 
gambiae pyrethroid susceptible Kisumu and pyrethroid resistant Zenet strain. Three-minute exposure and 72 h holding. c Tunnel tests with 
unwashed and washed Interceptor G2 netting against Anopheles gambiae pyrethroid susceptible (Kimumu) and pyrethroid resistant (Zenet) 
mosquitoes: % passage, % feeding, % mortality






























0 wash 20 wash 0 wash 20 wash















Suscepble Resistant Suscepble Resistant Suscepble Resistant Resistant









Interceptor G2          0
washes





Page 12 of 15Tungu et al. Malar J          (2021) 20:180 
In further supplementary 3  min cone tests using the 
susceptible strain, mortality was 100% on unwashed 
IG1 and IG2, and on the IG1 and IG2 washed 20 times 
mortality was reduced to 82% and 86%, respectively. 
With the Zenet pyrethroid resistant strain, cone mortal-
ity was reduced to 16% and 40% with unwashed IG1 and 
IG2, respectively, and 16% and 20% respectively after 20 
washes (Fig. 3b).
Supplementary tunnel tests were conducted using sus-
ceptible and resistant strains tested on unwashed IG2 
and IG2 washed 20 times (Fig. 3c). With untreated net-
ting, 100% of the susceptible and 86% of the resistant 
mosquitoes penetrated the holes into the baited chamber, 
100% of the susceptible and 69% of the resistant mosqui-
toes blood-fed, and 2% of the susceptible and 2% of the 
resistant mosquitoes died. With unwashed IG2 netting 
fewer of the susceptible (89%) and resistant (38%) mos-
quitoes penetrated the holes, and even fewer susceptible 
(70%) and resistant (0%) mosquitoes’ blood-fed. How-
ever, 98% of the susceptible and 36% of the resistant mos-
quitoes were killed by the unwashed IG2 their attempts 
to feed. With the IG2 washed 20 times, a smaller percent-
age of the susceptible (65%) and resistant (20%) mosqui-
toes penetrated the holes (surprisingly), fewer susceptible 
(18%) and resistant (0%) blood-fed, and yet 100% of sus-
ceptible and 26% of resistant mosquitoes were killed by 
the IG2 washed 20 times. The newcomer Zenet strain 
was evidently less well adapted to the tunnel test, pen-
etrating holed netting and responding/feeding on guinea 
pigs less well than did the long-established Kisumu.
Comparison of supplementary bioassay tests with hut trial 
results
Comparing the laboratory cone and tunnel bioassay 
results against the pyrethroid resistant An gambiae s.s. 
strain and the experimental hut results against the wild 
pyrethroid resistant An funestus population, both types 
of bioassay predicted the response in the hut to the 
pyrethroid-only IG1: mortality was 16% in the cone and 
13% in the hut against the unwashed IG1, and 16% in the 
cone and 11% in the hut against the IG1 20 times washed 
(averaged control-corrected mortality). When tested 
against the unwashed IG2, mortality was 40% in the cone, 
36% in the tunnel and 51% in the hut; when tested with 
the 20 times washed IG2 mortality was 20% in the cone, 
26% in the tunnel and 46% in the hut.
With the unwashed and washed IG2, percentage pas-
sage and percentage blood-feeding in the tunnel test 
were significantly lower with the newly-colonised resist-
ant Zenet strain as compared to the long-established 
susceptible Kisumu strain. While up to 70% of Kisumu 
blood-fed after penetrating the IG2 netting, none (0%) 
of the Zenet strain blood-fed through IG2. And while 
high mortality of Kisumu (up to 70%) was recorded with 
IG2, low mortality was recorded against unwashed and 
washed IG2 (36% and 26%, respectively). This very much 
reflected the new adaptation of the Zenet strain to the 
tunnel test, possibly an avoidance or irritation of the 
treated net, or ‘reluctance’ to feed on guinea pigs. How-
ever, for those Zenet strain mosquitoes that did penetrate 
the netting, mortality inflicted by unwashed and 20 times 
washed IG2 was high, 58% and 80% respectively, and 
more closely resembled mortality in experimental huts.
This series of bioassay tests demonstrates that the chlo-
rfenapyr component of IG2 LN makes the major contri-
bution to controlling pyrethroid resistant An. gambiae 
and An. funestus. The tunnel tests were more predictive 
of efficacy in experimental huts whilst cone bioassays 
were less predictive.
Discussion
Novel alternative insecticides which can complement the 
pyrethroids on LLIN and improve the control of pyre-
throid resistant vectors are urgently needed to sustain 
progress against malaria. The objective of the present 
study was to determine the efficacy and wash-fastness of 
the chlorfenapyr-alphacypermethrin mixture net, Inter-
ceptor G2 LN, unwashed and after 20 washes, against 
the primary pyrethroid-resistant vectors An. funestus 
and An. gambiae s.s. under household-like conditions 
compared to the standard pyrethroid-only net Inter-
ceptor LN (IG1). Previously this very team had partici-
pated in the development and evaluation of IG1 against 
An. funestus and An. gambiae s.s. 10–14 years ago when 
these species were pyrethroid susceptible in NE Tanzania 
[8, 20]. Latterly this team`s participation was extended 
to development and evaluation of the new generation 
long-lasting net IG2 against the An. gambiae sibling 
species An. coluzzii in Benin, W Africa, and An. arabi-
ensis in Kilimananjaro, Tanzania, where the species had 
become pyrethroid resistant [13–17]. Two trials were 
more recently extended to Muheza, NE Tanzania, aimed 
at evaluating IG2 against pyrethroid resistant An. gam-
biae s.s. and An. funestus. Only An. funestus was caught 
in significant numbers. In the meta-analysis of the two 
trials, the mortality induced by IG2 against An. funestus 
was 3.4 times higher than with untreated nets and 2.3 
times higher than with IG1. The comparison of mosquito 
mortality between the unwashed IG2 and IG2 washed 
20 times produced a relative risk of 1.04 (CI 0.83–1.30) 
indicating no loss of efficacy of IG2 over 20 washes. This 
means IG2 exceeds by a factor of 2.3 the mortality crite-
rion required by WHO PQT to grant the product LLIN 
status [32]. The comparison of chlorfenapyr CTN with 
IG2 confirmed that the chlorfenapyr component of IG2 
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was the main contributor to mosquito mortality and net 
efficacy. However, it was also confirmed that the pyre-
throid continues to have a valuable role with respect to 
blood-feeding inhibition, repellency and personal protec-
tion. The pyrethroid contributed 39% protection against 
blood-feeding of pyrethroid-resistant An. funestus in IG1 
and 30% protection in IG2 compared to untreated nets. 
This was not far short of the 32% blood-feeding inhibi-
tion shown by IG1 against pyrethroid-susceptible An. 
funestus in Zenet hut trials over 10 years ago [20].
More important than the demonstration of equiva-
lence of blood-feeding inhibition in resistant An. funes-
tus was the clear demonstration of superior mortality 
of IG2 against resistant An. funestus that approached 
the mortality that IG1 once showed against An. funes-
tus and An. gambiae s.s. in NE Tanzania before resist-
ance evolved. In 2010, IG1 induced a control-corrected 
mortality of 80% among susceptible An. funestus when 
unwashed and 60% after 20 washes. In 2015–2016, IG1 
only induced a control-corrected mortality of 12% among 
pyrethroid resistant An. funestus unwashed and of 11% 
after 20 washes. In contrast, IG2 induced a control-cor-
rected mean mortality of 49% among pyrethroid resistant 
An. funestus when unwashed and 52% after 20 washes. 
While the performance of unwashed IG2 did fall a little 
short of the mortality induced by unwashed IG1 in 2006 
against susceptible An. funestus, the mortality that the 
20-times washed IG2 demonstrated against resistant An. 
funestus in 2016 was comparable to the efficacy 20-times 
washed IG1 demonstrated against susceptible An. funes-
tus in 2006. Other recent experimental hut trials in West 
Africa in which IG2 has generated high mortality include 
An. coluzzii in Benin (71%, 65%), in Burkina Faso (76%, 
75%) and Côte d’Ivoire (90%, 82%) when unwashed and 
washed 20 times, respectively. This is comparable mortal-
ity to that achieved with IG1 and other pyrethroid-only 
nets in the 1990s and new millennium when standard 
ITN and LLIN were first demonstrating malaria control 
and personal protection [37]. Considering the impact of 
ITN and LLIN then, it is reasonable to anticipate that IG2 
and other Dual-AI will achieve comparative control of 
pyrethroid-resistant mosquitoes as standard LLIN once 
did against susceptible mosquitoes.
It is certainly the case that high intensity resistance 
means that standard LLIN are no longer preventing 
malaria as they once did. In countries and regions bor-
dering Lake Victoria, for example, standard LLIN no 
longer appear to be reducing malaria despite mainte-
nance of high coverage [9, 38, 39]. A cluster randomised 
trial of standard pyrethroid LLIN conducted in the region 
of high resistance, Kagera, on the western shore of Lake 
Victoria, Tanzania, could only demonstrate stasis in 2018 
after introduction of new pyrethroid-only LLIN [9] but 
in adjacent clusters which were randomised to receive 
pyrethroid-PBO synergist LLIN there was a significant 
reduction in entomological inoculation rate and malaria 
prevalence [10].
The only putative insecticide mixture LLIN on the 
horizon, apart from the pyrethroid-chlorfenapyr net IG2, 
is a net treated with pyrethroid and pyriproxifen which 
is a mosquito sterilant and insect growth regulator. In a 
stepped wedge cluster randomised trial conducted in 
Burkina Faso a reduced malaria incidence rate of 12% 
was observed in the intervention arm compared to the 
control, a standard pyrethroid-only LLIN [40, 41]. As 
a mixture of two adulticides, IG2 would appear to hold 
more promise. Owing to the diversity of novel AI and 
modes of action being tested on LLINs, the WHO is no 
longer willing to accept entomological evidence as gener-
ated in experimental hut trials as adequate evidence for 
recommendation of a novel LLIN class. Since 2017, the 
WHO has required all new classes of LLIN to be subject 
to cluster randomized trials (CRT) with malaria control 
outcomes before they can gain approval or recommen-
dation for wide-scale use as new methods of malaria 
control [42]. Chlorfenapyr is currently the only novel 
adulticide being evaluated on LLIN in a CRT. Such a trial 
takes at least 2 years to complete. This means that chlo-
rfenapyr is a very precious AI, squandered at our peril. 
If chlorfenapyr fails due to evolution of resistance, there 
will be only PBO and piriproxyfen left in the armoury for 
use on nets. Fortunately, chlorfenapyr is novel chemistry 
and there is no sign of resistance so far, but resistance will 
evolve just as it always does. What must be done now is 
to identify ways preserve this AI as much as it is used to 
good effect. There is temptation to use it as an IRS insec-
ticide too. In hut trials, it appears less effective applied as 
an IRS adulticide and the WHO proposes cluster rand-
omized trial evidence of malaria effect [43, 44]. Blanket 
IRS coverage may accelerate resistance selection, as was 
demonstrated after 7  years of pyrethroid IRS in Kagera 
region that led to premature loss of pyrethroid effective-
ness in LLIN just as LLIN were being scaled up [9, 10]. 
What is needed is a far-sighted resistance management 
strategy which prioritizes PBO, chlorfenapyr, and the few 
AI that can be used safely on nets and reduces their use 
in other applications, like IRS, if there are good alterna-
tives that can be used or rotated to reduce selection pres-
sure on chlorfenapyr in IG2.
Conclusion
Novel alternative insecticides suitable that can comple-
ment the pyrethroids and improve the control of pyre-
throid resistant malaria vectors are urgently required 
for sustaining LLIN as a means of malaria control. The 
mortality of pyrethroid resistant An. funestus induced by 
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unwashed and 20 times washed Interceptor G2 appears 
to meet the entomological requirements set by the WHO 
for efficacy and wash-resistance. Thus far there is no 
epidemiological evidence to back up the entomologi-
cal evidence nor any knowledge of how long Interceptor 
G2 LN or its chlorfenapyr component will remain effec-
tive under field conditions. Therefore, large-scale cluster 
randomized trials of Interceptor G2 with epidemiologi-
cal end-points are an essential next step. A CRT in NW 
Tanzania against An. funestus and An. gambiae is due to 
report in mid-2021 for recommendation as a new class of 
LLIN product to WHO.
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